Navigation Links
Meditor Pharmaceuticals (North American) Ltd. announces the closing of a merger agreement with American Medical Technologies, Inc.
Date:3/12/2009

TORONTO, March 12 /PRNewswire/ - Meditor Pharmaceuticals Ltd (Trading as M20.F) is pleased to announce it has concluded a merger agreement with AMERICAN MEDICAL TECHNOLOGIES, INC. (AMT).

AMERICAN MEDICAL TECHNOLOGIES, INC. is a U.S. based company which performs biomedical research dedicated to the development and commercialization of proprietary Blood Cell Morphometric Method (BCMM) technology. Its purpose is to detect early cancer in patients where traditional methods do not work.

As a result of the continuous scientific research activity since 1985 a comprehensive Patent was filed in Russia for a "Method for diagnosing human tumor disorders".

Our method, which has already proved to be beneficial to hundreds of patients, reduces the risk for the planned clinical trials and shortens the time to the market. Upon the completion of the automatic analysis and before all the clinical trials are completed, our technology can be applied to many countries and has unlimited use in the alternative medicine market today.

AMT's Research and Development operations are based in USA, Germany and Ukraine, and conducted through the lab in New York and clinical applications in Ukraine. AMT's management team consists of Dr. Boris Farber (CEO and Chairman of the Board), Dr. Evgenia Skobeltzin (Leading Scientist R&D), and Tatiana Skobeltzin (Administration Manager, Germany).

According to Dr. Farber, with our unique Blood Cell Morphometric Method, we will be able to provide new and effective technology to deal with early cancer detection in healthy individuals and monitor the treatment efficiency in patients diagnosed with cancer. This will revolutionize the field of oncology and may become a new standard of care in this $219.2 billion market.

In additional news, Mr. Larry Skolnik, President of MEDITOR and Dr. Boris Farber, CEO and Chairman of AMT are continuing to develop relationships with market makers in Europe to help create
'/>"/>

SOURCE Meditor Pharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Gamma Pharmaceuticals Accepts PO From Leading St. Louis Missouri Distributor. Order Valued up to $850,000 Retail Market Value
2. MAP Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
3. Valeant Pharmaceuticals to Present at Cowen and Company 29th Annual Health Care Conference
4. ISTA Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
5. Biostar Pharmaceuticals, Inc. Completes 8.6-Acre Land Purchase to House New Raw Materials Processing Plant
6. Celator(R) Pharmaceuticals Enrolls First Patient in Its Phase 2 Study of CPX-351 in Acute Myeloid Leukemia in First Relapse
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Cowen & Companys 29th Annual Health Care Conference in Boston on March 16, 2009
8. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
9. Savient Pharmaceuticals to Present at The Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
10. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
11. Merz Aesthetics, a Division of Merz Pharmaceuticals USA, Introduces a Universal Language of Aging for Use in Education, Research and Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Liberty University has received accreditation ... program from the Council for Accreditation of Counseling & ... Liberty’s Center for Counseling & Family Studies , is ... the university’s new School of Behavioral Sciences. Prior to the ...
(Date:1/22/2015)... 22, 2015 Gabe’s Chemo Duck Program is pleased ... first app ever created for kids with cancer. The Chemo Duck ... devices, is filled with enjoyable games to help children of all ... free app helps to keep kids entertained, educated and at ease ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Angelweddingdress is a ... business invites its customers to follow it on Facebook, Twitter, ... a Valentine’s Day gift. Angelweddingdress draws a lottery every week. ... Sale to Feb. 28, 2015. Click Angelweddingdress homepage ...
(Date:1/22/2015)... 22, 2015 Juvent Sports ( http://www.juventsports.com ... 2015 PGA Merchandise Show to bestow a Juvent Sports ... amateur golfer, Arlene McKitrick. The award commemorated and congratulated ... tournament win. She won her first amateur tournament in ...
(Date:1/22/2015)... 22, 2015 For over 20 years, Dr. David ... and Vista area has treated just about every type of ... circumstances. And for those same twenty-plus years, the team at ... those injuries with the best possible doctor. With the ...
Breaking Medicine News(10 mins):Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2
... hernia surgeries in 13 hours, 41 minutes and 19 seconds ... // ,The surgeon Dr J S Rajkumar, chairman, Lifeline ... surgeries in 24 hours. ,The patients on whom ... exercise was backed by a team of dedicated professionals and ...
... Recent studies conducted on bird flu vaccine has now established that ... bird flu crisis may not be as effective as it is ... the companies developing such a vaccine named as generic H5N1 and ... be in production by the end of the year, and is ...
... Heart and Stroke Foundation of Canada has issued a wake up ... in the advancement of heart health. // ,Dr. Beth ... that the rates of obesity in baby boomers have soared by ... inactive." ,Abramson feels that baby boomers, the group between ...
... of great joy and expectation as both the expectant mother ... women however are not able to experience the bliss due ... more than psychological distress. A few of the factors that ... special report. , Abuse during pregnancy: Abuse ...
... coffee, it as been found in a study that drinking coffee ... that consumption should be moderate. Its moderate consumption every day may ... ,Previous studies in US had linked drinking more than two cups ... of chronic liver disease. ,This new study by Harvard ...
... spurred by the inability or failure to ‘Gasp’. But now, ... probable cause of SIDS. // ,University of Bristol ... that are capable of producing nervous impulses on their ... ‘pacemakers.' ,The research team, led by Professor Julian Paton ...
Cached Medicine News:Health News:Do Women Die In Childbirth Because It Is More Preferable? 2Health News:Do Women Die In Childbirth Because It Is More Preferable? 3
(Date:1/23/2015)... Gem Pharmaceuticals announced today that the initial soft ... Company,s Phase 2 clinical trial.  This open-label study will ... GPX-150 (an investigational medication), in approximately 30 adults as ... Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO GPX-150 ...
(Date:1/22/2015)... MINNEAPOLIS, Jan. 22, 2015  Uroplasty, Inc. (NASDAQ: UPI ... markets innovative proprietary products to treat voiding dysfunctions, today ... ended December 31, 2014.  Global revenue for the ... $4.4 million, a new quarterly revenue record, as compared ...
(Date:1/22/2015)... 22, 2015  Profil Institute for Clinical Research, Inc., a ... announced today a new textbook,  Translational Research Methods for ... a leading global scientific publisher. The textbook ... for use in early phase clinical studies of new ...
Breaking Medicine Technology:Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 2New Textbook "Translational Research Methods for Diabetes, Obesity and Cardiometabolic Drug Development" Provides Critical Review Of Current And Emerging Clinical Investigation Methods 3
... April 16, 2012 genae, a leading Contract ... industries, today announced that Catalina Trana, MD, has been appointed ... responsible for all clinical, safety and risk management related to ... Catalina, whose extensive clinical and research expertise will be of ...
... subsidiary of Eisai Inc., announced today that it has ... and efficacy of MORAb-004 in the treatment of metastatic ... MORAb-004 is a monoclonal antibody that specifically binds to ... is a randomized, double-blind, placebo-controlled study to assess the ...
Cached Medicine Technology:genae Appoints Chief Medical Officer 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer 3
Used to provide drainage of urine from the bladder. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open packages. Inte...
... Used for temporary ... ureteropelvic junction to the ... Supplied sterile in peel-open ... use. CAUTION: Periodic evaluation ...
Used for stenting the urethra during hypospadias or epispadias repair and to allow post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Used for stenting the urethra after hypospadias or epispadias repair and to provide post-operative drainage of the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: